Paloma Partners Management Co bought a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 10,040 shares of the company’s stock, valued at approximately $80,000.
A number of other hedge funds also recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its position in Tango Therapeutics by 12.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,771 shares of the company’s stock valued at $102,000 after purchasing an additional 1,426 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Tango Therapeutics by 3.4% during the 1st quarter. Vanguard Group Inc. now owns 3,080,885 shares of the company’s stock valued at $24,462,000 after buying an additional 101,673 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in shares of Tango Therapeutics during the 1st quarter valued at $272,000. SG Americas Securities LLC increased its stake in shares of Tango Therapeutics by 16.0% in the first quarter. SG Americas Securities LLC now owns 30,429 shares of the company’s stock worth $242,000 after acquiring an additional 4,203 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Tango Therapeutics by 32.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company’s stock worth $230,000 after acquiring an additional 7,128 shares in the last quarter. Hedge funds and other institutional investors own 78.99% of the company’s stock.
Wall Street Analysts Forecast Growth
TNGX has been the subject of several research reports. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Tango Therapeutics in a report on Tuesday, July 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a research report on Tuesday, July 9th. Jefferies Financial Group began coverage on shares of Tango Therapeutics in a research note on Wednesday, July 17th. They set a “buy” rating and a $19.00 price target on the stock. Barclays reduced their price objective on shares of Tango Therapeutics from $18.00 to $13.00 and set an “overweight” rating for the company in a research note on Friday, May 24th. Finally, Wedbush cut their target price on Tango Therapeutics from $18.00 to $11.00 and set an “outperform” rating on the stock in a report on Thursday, May 23rd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $14.86.
Insider Buying and Selling
In other Tango Therapeutics news, insider Mva Investors, Llc sold 63,000 shares of the stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $7.24, for a total value of $456,120.00. Following the completion of the sale, the insider now directly owns 420,524 shares of the company’s stock, valued at approximately $3,044,593.76. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider Mva Investors, Llc sold 63,000 shares of the company’s stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $7.24, for a total value of $456,120.00. Following the completion of the transaction, the insider now directly owns 420,524 shares in the company, valued at $3,044,593.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Rock Ventures Iv L.P. Third sold 200,000 shares of the stock in a transaction on Wednesday, July 24th. The shares were sold at an average price of $9.82, for a total transaction of $1,964,000.00. Following the completion of the transaction, the insider now owns 17,872,074 shares of the company’s stock, valued at approximately $175,503,766.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,350,642 shares of company stock valued at $12,620,455. 6.20% of the stock is owned by company insiders.
Tango Therapeutics Stock Performance
Shares of NASDAQ:TNGX traded down $0.07 during midday trading on Tuesday, hitting $9.69. The company’s stock had a trading volume of 240,497 shares, compared to its average volume of 686,768. Tango Therapeutics, Inc. has a fifty-two week low of $3.05 and a fifty-two week high of $13.03. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -8.64 and a beta of 0.83. The stock’s 50 day simple moving average is $8.57 and its 200 day simple moving average is $9.21.
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). Tango Therapeutics had a negative net margin of 299.88% and a negative return on equity of 44.35%. The business had revenue of $6.47 million during the quarter, compared to analyst estimates of $7.13 million. As a group, analysts anticipate that Tango Therapeutics, Inc. will post -1.33 EPS for the current year.
Tango Therapeutics Company Profile
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
See Also
- Five stocks we like better than Tango Therapeutics
- Low PE Growth Stocks: Unlocking Investment Opportunities
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- What Are Dividend Contenders? Investing in Dividend Contenders
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- What Investors Need to Know About Upcoming IPOs
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Want to see what other hedge funds are holding TNGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tango Therapeutics, Inc. (NASDAQ:TNGX – Free Report).
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.